iShares US Pharmaceuticals ETF
128 hedge funds and large institutions have $117M invested in iShares US Pharmaceuticals ETF in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 15 increasing their positions, 34 reducing their positions, and 5 closing their positions.
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
7% more funds holding
Funds holding: 120 → 128 (+8)
2.8% more ownership
Funds ownership: 97.38% → 100.18% (+2.8%)
5% less capital invested
Capital invested by funds: $122M → $117M (-$5.51M)
56% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
+$6.78M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.35M |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
+$634K |
| 4 |
OCM
One Capital Management
Westlake Village,
California
|
+$394K |
| 5 |
SWA
Stratos Wealth Advisors
Beachwood,
Ohio
|
+$343K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.66M |
| 2 |
Fisher Asset Management
Camas,
Washington
|
-$3.73M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$3.43M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.04M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$1.02M |
IHE Hedge Fund Activity: Q3 2023 in Review
128 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q3 2023, worth a combined $117M — down 4.5% from $122M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new IHE positions and 5 closed out — a net gain of 8 holders — while 15 added to existing stakes and 34 trimmed.
The largest buyer was Envestnet Asset Management, adding an estimated $6.78M. The largest seller was Susquehanna International Group, cutting an estimated $4.66M.
- 128 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q3 2023, up from 120 in Q2 2023.
- Funds reported $117M of iShares US Pharmaceuticals ETF stock for Q3 2023, down 4.5% quarter-over-quarter.
- 13 funds opened new iShares US Pharmaceuticals ETF positions in Q3 2023 and 5 closed out, a net change of +8 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q3 2023 was Envestnet Asset Management, an estimated $6.78M added.
- The largest iShares US Pharmaceuticals ETF seller in Q3 2023 was Susquehanna International Group, an estimated $4.66M sold.
Based on aggregated 13F filings for Q3 2023.